[Thaïlande] Thailand announces plans for human trials after developing its second COVID-19 vaccine

Auteur : Roy Chiang

Production : Healthcare IT News, the industry’s authoritative source covering the people, policy and technology driving next-generation healthcare in the U.S. and throughout the world. Since 2003, it has been the voice of health IT, delivering editorial insights about compelling topics such as electronic health records, health information exchange, privacy and security, data analytics, patient engagement, population health and revenue cycle management. Healthcare IT News is part of HIMSS Media.

Diffusion : site du journal Healthcare IT News.

Date et Heure : 23 février 2021, 02:34 AM

Following the production of its second domestically developed COVID-19 vaccine, Thailand is all set to commence its human trials from as early as April this year.

The vaccine which was developed by Chulalongkorn University showed promising results in prior trials with mice and monkeys. The University’s Centre of Excellence in Vaccine Research and Development is utilizing new mRNA technology and its clinical testing on transgenic mice showed that the vaccine was able to prevent clinical symptoms and viremia after two shots. The university is looking to enroll 72 participants in the first phase of the human trials and subsequently increase the number to 300-600 participants in the second phase. The university has also begun research on a second-generation vaccine that will help grant additional protection to its citizens against the UK and South African variants of the COVID-19 virus.

Source : Roy Chiang, « Thailand announces plans for human trials after developing its second COVID-19 vaccine », Healthcare IT News, 23/02/2021. URL : https://www.healthcareitnews.com/news/asia-pacific/thailand-announces-plans-human-trials-after-developing-its-second-covid-19-vaccine (consulté le 23/02/2021).

Photo « à la une » :  Thailand announces plans for human trials. © Pexels


Vous aimerez aussi...

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

Rechercher dans OpenEdition Search

Vous allez être redirigé vers OpenEdition Search